Phio Pharmaceuticals Corp. (PHIO)
NASDAQ: PHIO · IEX Real-Time Price · USD
0.726
-0.004 (-0.53%)
At close: Mar 27, 2024, 4:00 PM
0.710
-0.016 (-2.22%)
Pre-market: Mar 28, 2024, 4:00 AM EDT
Company Description
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States.
The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells.
The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018.
Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Phio Pharmaceuticals Corp.
Country | United States |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 9 |
CEO | Robert J. Bitterman |
Contact Details
Address: 257 Simarano Drive, Suite 101 Marlborough, Massachusetts 01752 United States | |
Phone | (508) 767-3861 |
Website | phiopharma.com |
Stock Details
Ticker Symbol | PHIO |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001533040 |
CUSIP Number | 71880W303 |
ISIN Number | US71880W4024 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Robert J. Bitterman | President, Chief Executive Officer and Chairman |
Caitlin Kontulis | Vice President of Finance and Administration and Secretary |
Linda M. Mahoney | Senior Vice President of Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 26, 2024 | 8-K | Current Report |
Dec 28, 2023 | 424B3 | Prospectus |
Dec 27, 2023 | EFFECT | Notice of Effectiveness |
Dec 19, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |
Dec 19, 2023 | D | Notice of Exempt Offering of Securities |
Dec 8, 2023 | 8-K | Current Report |
Nov 9, 2023 | 8-K | Current Report |
Nov 9, 2023 | 10-Q | Quarterly Report |
Sep 29, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |